Breanna Campbell, MD
Infectious Disease · Baton Rouge, LANPI 1295112597
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.0% of the total across 56 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 18 manufacturers, the largest accounting for just 19.4% — the pattern of someone who eats at a lot of different presentations.
Across 56 payments — averaging $22.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$242
- Astellas Pharma US Inc$205
- Melinta Therapeutics, LLC$165
- Paratek Pharmaceuticals, Inc.$154
- Kerecis Limited$71
- Shionogi Inc$69
- plus $344 from 12 others
What the payments were for
- Food & beverage$1,18795%
- Education$635%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 15 | $242 |
| Astellas Pharma US Inc | 7 | $205 |
| Melinta Therapeutics, LLC | 5 | $165 |
| Paratek Pharmaceuticals, Inc. | 8 | $154 |
| Kerecis Limited | 2 | $71 |
| Shionogi Inc | 3 | $69 |
| Smith+Nephew | 2 | $50 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $47 |
| Merck | 2 | $37 |
| Evoke Pharma, Inc. | 2 | $36 |
| Insmed, Inc. | 1 | $28 |
| Acera Surgical, Inc. | 1 | $27 |
| BD | 1 | $26 |
| Aimmune Therapeutics, Inc. | 1 | $25 |
| Lifenet Health | 1 | $23 |
| Stryker | 1 | $16 |
| Vertex | 1 | $15 |
| AstraZeneca | 1 | $14 |
How this compares
$1,250 in reported general payments places this provider in the 60th percentile of 105 infectious disease providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Daptomycin | 77 | $48,849 |
| CeftriaxoneCeftriaxone Sodium | 127 | $12,360 |
| Ampicillin Sodium | 22 | $7,954 |
| Vancomycin Hcl | 28 | $5,564 |
| ErtapenemErtapenem Sodium | 12 | $3,124 |
| Linezolid | 20 | $1,789 |
| Cefazolin Sodium | 24 | $1,019 |
| Fluconazole | 15 | $593 |
| Doxycycline Hyclate | 30 | $449 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 14 | $318 |
| Amoxicillin | 12 | $226 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Baton Rouge
- Walter CampbellBaton Rouge$6K
- Waref AzmehBaton Rouge$2K
- Maria Reyes AngelesBaton Rouge$2K
- Patrick NjokuBaton Rouge$979
- Scott AndersonBaton Rouge$937
- Shobha Rani VootukuriBaton Rouge$881
- Madeleine HeckBaton Rouge$611
- John NnadiBaton Rouge$491
- Hector Brunet RodriguezShreveport$592K
- Guillermo Padilla-PinedaShreveport$106K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.